A Disease Registry of Patients With Mantle Cell Lymphoma

Inclusion Criteria:

1. Patient diagnosed with Mantle Cell Lymphoma (MCL)
2. Informed consent for participation
3. Age ≥ 18 years old, as of the first observed diagnosis of MCL

Patients for whom a clinical decision has been made to initiate novel therapy in the last 6 months, limited to the following novel agent categories:

1. Bcl-2 inhibitors
2. BTK inhibitors
3. Immunomodulatory agents
4. Phosphoinositide 3-kinase inhibitors The novel agent must have been granted approval in at least one haematological cancer. Treatment must be ongoing at the time of enrollment.

Exclusion Criteria:

• Patient is participating in a clinical study that prohibits participation in non-interventional studies, or where treatment is blinded, at the time of consent.